[ad_1]
DUBLIN, July 7, 2023 /PRNewswire/ — The “Digital Dose Inhalers: Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.
The global market for Digital Dose Inhalers estimated at US$2.9 Billion in the year 2022, is projected to reach a revised size of US$7.2 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2022-2030.
Metered Dose, one of the segments analyzed in the report, is projected to record 11.4% CAGR and reach US$4.4 Billion by the end of the analysis period.
Taking into account the ongoing post pandemic recovery, growth in the Dry Powder segment is readjusted to a revised 13.2% CAGR for the next 8-year period.
The U.S. Market is Estimated at $1.2 Billion, While China is Forecast to Grow at 15% CAGR
The Digital Dose Inhalers market in the U.S. is estimated at US$1.2 Billion in the year 2022. China, the world’s second largest economy, is forecast to reach a projected market size of US$669.8 Million by the year 2030 trailing a CAGR of 15% over the analysis period 2022 to 2030.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.1% and 10.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 11.6% CAGR.
Select Competitors (Total 53 Featured) –
- AptarGroup, Inc.
- AstraZeneca plc
- CHIESI Farmaceutici S.p.A.
- Cipla Inc.
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals Ltd.
- H&T Presspart Manufacturing Ltd.
- Koninklijke Philips N.V.
- Lupin Ltd.
- Novartis International AG
- Teva Pharmaceutical Industries Ltd.
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Impact of COVID-19 Pandemic and Looming Global Recession; Living with COVID-19, the New Normal
- Stagflation and Risk of Recession: New Challenges Emerge for the Global Market in 2022 & 2023
- World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020, 2021, 2022 and 2023
- COVID-19 Healthcare Emergency Highlights Critical Significance of Digital Dose…
[ad_2]
